This is an old revision of this page, as edited by Rjwilmsi(talk | contribs) at 16:25, 30 January 2016(→top: Journal cites: format journal names, using AWB (11852)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 16:25, 30 January 2016 by Rjwilmsi(talk | contribs)(→top: Journal cites: format journal names, using AWB (11852))
However, the effects of the compound on experimental animals appear less encouraging.[6] It has been detected as an apparent designer drug,[7] along with the related 3-chloroamphetamine, which is even more potent as a releaser of dopamine and serotonin but slightly less neurotoxic.[8][9][10][11][12]
The closely related N-methylated derivative, para-Chloromethamphetamine (CMA), which is metabolised to para-chloroamphetamine in vivo, has neurotoxic properties as well.
Legal Status
China
As of October 2015 4-CA is a controlled substance in China.[13]
^Miller, K. J.; Anderholm, D. C.; Ames, M. M. (1986). "Metabolic activation of the serotonergic neurotoxin para-chloroamphetamine to chemically reactive intermediates by hepatic and brain microsomal preparations". Biochemical Pharmacology. 35 (10): 1737–1742. doi:10.1016/0006-2952(86)90332-1. PMID3707603.
^Gal, E. M.; Cristiansen, P. A.; Yunger, L. M. (1975). "Effect of p-chloroamphetamine on cerebral tryptophan-5-hydroxylase in vivo: A reexamination". Neuropharmacology. 14 (1): 31–9. doi:10.1016/0028-3908(75)90063-5. PMID125387.
^Freo, U; Pietrini, P; Pizzolato, G; Furey, M; Merico, A; Ruggero, S; Dam, M; Battistin, L (1995). "Cerebral metabolic responses to clomipramine are greatly reduced following pretreatment with the specific serotonin neurotoxin para-chloroamphetamine (PCA). A 2-deoxyglucose study in rats". Neuropsychopharmacology. 13 (3): 215–22. doi:10.1016/0893-133X(95)00053-G. PMID8602894.
^Alexander T. Shulgin (1978). Leslie L. Iversen, Susan D. Iversen, and Solomon H. Snyder (ed.). Handbook of Psychopharmacology. Vol. 11: Stimulants. New York: Plenum Press.{{cite book}}: CS1 maint: multiple names: editors list (link)
^Lin TC, Lin DL, Lua AC; Lin; Lua (2011). "Detection of p-chloroamphetamine in urine samples with mass spectrometry". Journal of Analytical Toxicology. 35 (4): 205–210. doi:10.1093/anatox/35.4.205. PMID21513613.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^Fuller, R.; Schaffer, R. J.; Roush, B. W.; Molloy, B. B. (1972). "Drug disposition as a factor in the lowering of brain serotonin by chloroamphetamines in the rat". Biochemical Pharmacology. 21 (10): 1413–1417. doi:10.1016/0006-2952(72)90365-6. PMID5029422.
^Ögren, S. O.; Ross, S. B. (2009). "Substituted Amphetamine Derivatives. II. Behavioural Effects in Mice Related to Monoaminergic Neurones". Acta Pharmacologica et Toxicologica. 41 (4): 353–368. doi:10.1111/j.1600-0773.1977.tb02674.x. PMID303437.
^Ross, S. B.; Kelder, D. (2009). "Inhibition of 3H-Dopamine Accumulation in Reserpinized and Normal Rat Striatum". Acta Pharmacologica et Toxicologica. 44 (5): 329–335. doi:10.1111/j.1600-0773.1979.tb02339.x. PMID474143.
^Fuller, R. W.; Baker, J. C. (1974). "Long-lasting reduction of brain 5-hydroxytryptamine concentration by 3-chloroamphetamine and 4-chloroamphetamine in iprindole-treated rats". Journal of Pharmacy and Pharmacology. 26 (11): 912–914. doi:10.1111/j.2042-7158.1974.tb09206.x. PMID4156568.
^Ross, S. B.; Ögren, S. O.; Renyi, A. L. (2009). "Substituted Amphetamine Derivatives. I. Effect on Uptake and Release of Biogenic Monoamines and on Monoamine Oxidase in the Mouse Brain". Acta Pharmacologica et Toxicologica. 41 (4): 337–352. doi:10.1111/j.1600-0773.1977.tb02673.x. PMID579062.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.